Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH)’s share price traded up 2.8% during trading on Thursday . The stock traded as high as $4.06 and last traded at $4.01, with a volume of 273,765 shares trading hands. The stock had previously closed at $3.90.

Several equities analysts have recently commented on the company. Wedbush restated a “neutral” rating and set a $11.00 price target (up previously from $8.00) on shares of Tetraphase Pharmaceuticals in a research note on Thursday, May 5th. Needham & Company LLC restated a “hold” rating on shares of Tetraphase Pharmaceuticals in a research note on Saturday, May 14th. Zacks Investment Research lowered Tetraphase Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, July 14th. Finally, Gabelli restated a “neutral” rating on shares of Tetraphase Pharmaceuticals in a research note on Monday, May 16th. Twelve equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $14.85.

The firm has a 50 day moving average of $4.16 and a 200 day moving average of $4.46. The firm’s market capitalization is $148.99 million.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last announced its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.47) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.46) by $0.01. The firm earned $1.20 million during the quarter, compared to analyst estimates of $2.05 million. The firm’s revenue was down 63.6% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.72) earnings per share. On average, analysts forecast that Tetraphase Pharmaceuticals Inc. will post ($1.95) EPS for the current year.

A hedge fund recently raised its stake in Tetraphase Pharmaceuticals stock. California Public Employees Retirement System raised its stake in shares of Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) by 1,459.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 276,000 shares of the biopharmaceutical company’s stock after buying an additional 258,300 shares during the period. California Public Employees Retirement System owned approximately 0.76% of Tetraphase Pharmaceuticals worth $2,768,000 as of its most recent filing with the SEC.

Tetraphase Pharmaceuticals, Inc (Tetraphase) is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. It is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.